Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $14.16

Aligos Therapeutics, Inc. (NASDAQ:ALGS) shares gapped down before the market opened on Thursday . The stock had previously closed at $14.16, but opened at $12.81. Aligos Therapeutics shares last traded at $11.91, with a volume of 287,405 shares.

Wall Street Analyst Weigh In

Separately, HC Wainwright initiated coverage on Aligos Therapeutics in a report on Monday, August 19th. They set a “buy” rating and a $75.00 target price on the stock.

Aligos Therapeutics Stock Performance

The stock has a market cap of $827.97 million, a price-to-earnings ratio of -9.17 and a beta of 2.18. The company has a 50 day moving average of $13.31 and a 200-day moving average of $16.46.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, beating the consensus estimate of ($4.00) by $4.75. The firm had revenue of $1.06 million during the quarter. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. During the same period in the prior year, the company earned ($10.75) earnings per share. On average, research analysts anticipate that Aligos Therapeutics, Inc. will post -8.15 EPS for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

Several hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC boosted its holdings in Aligos Therapeutics by 26.1% in the 2nd quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock worth $289,000 after acquiring an additional 171,490 shares during the period. Opaleye Management Inc. acquired a new position in Aligos Therapeutics during the 4th quarter valued at approximately $861,000. Altitude Crest Partners Inc. acquired a new position in shares of Aligos Therapeutics during the fourth quarter valued at $1,889,000. Finally, Armistice Capital LLC boosted its position in shares of Aligos Therapeutics by 5.3% during the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after buying an additional 363,000 shares during the period. Institutional investors and hedge funds own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).